Ongoing WARfarin and Coronary STENTing (WAR-STENT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified January 2010 by War-Stent Investigators.
Recruitment status was: Active, not recruiting

Sponsor:

Information provided by:

War-Stent Investigators

ClinicalTrials.gov Identifier:

NCT00722319

First received: July 23, 2008

Last updated: August 11, 2011

Last verified: January 2010

History of Changes

Purpose

Patients on warfarin treatment pose particular problems when undergoing percutaneous coronary intervention with stent implantation (PCI-S), because of the poor definition of the optimal antithrombotic strategies to be adopted both peri-procedurally and during the 4 (or more) weeks after PCI-S, when dual antiplatelet therapy with aspirin and clopidogrel is recommended. In the absence of solid evidence-based data, no definite recommendations for the management of this patient subset are currently given in the guidelines on percutaneous coronary intervention issued by the most prominent Cardiology Associations. Indeed, a high variability has been reported in the current antithrombotic strategies, which may consist in either the temporary substitution of warfarin by dual antiplatelet treatment or the combination of warfarin and aspirin or clopidogrel or both. Peri-procedural bridging therapy with either intravenous unfractionated or subcutaneous low-molecular-weight heparin is also variably carried out. Purpose of this registry is to determine in patients on warfarin treatment undergoing PCI-S: 1) the contemporary peri-procedural and medium-term antithrombotic management; and 2) the relative safety and efficacy of the various antithrombotic regimens.

Condition
Acute Coronary Syndrome Atrial Fibrillation


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.

Resource links provided by NLM:

Genetics Home Reference related topics: familial atrial fibrillation

MedlinePlus related topics: Blood Thinners

Drug Information available for: Warfarin Warfarin sodium

U.S. FDA Resources

Further study details as provided by War-Stent Investigators:

Primary Outcome Measures:

Incidence of major/minor bleeding + adverse cardiac events (i.e., need for urgent re-revascularization, myocardial infarction, death) + arterial/venous thrombosis/thromboembolism [ Time Frame: 1, 3, 6 and 12 months ]

Secondary Outcome Measures:

Incidence of major/minor bleeding [ Time Frame: 1, 3, 6 and 12 months ]
Adverse cardiac events (i.e., need for urgent re-revascularization, myocardial infarction, death) [ Time Frame: 1, 3, 6 and 12 months ]
Stent thrombosis [ Time Frame: 1, 3, 6 and 12 months ]
Arterial/venous thromboembolism; [ Time Frame: 1, 3, 6 and 12 months ]
Blood transfusions [ Time Frame: 1, 3, 6 and 12 months ]


Estimated Enrollment:	1000
Study Start Date:	March 2009
Estimated Study Completion Date:	October 2011
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts
A Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational

Detailed Description:

Patients on oral anticoagulation with vitamin-K antagonists who undergo PCI-S will be prospectively included in the registry and follow up for 12 months

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients treated with warfarin who are hospitalized at tertiary centers all over the country to undergo percutaneous coronary intervention with stent implantation

Criteria

Inclusion Criteria:

Patients with ongoing warfarin treatment.

Exclusion Criteria:

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00722319

Locations


Italy
Division of Cardiology
Bologna, Italy, 40133

Sponsors and Collaborators

War-Stent Investigators

Investigators


Study Director:	Andrea Rubboli, MD	Division of Cardiology, Maggiore Hospital, Bologna

More Information

Publications:

Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40(6):428-36. doi: 10.1080/07853890802089786. Review.

Rubboli A, Verheugt FW. Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting: a review of the available evidence and practical suggestions for the clinician. Int J Cardiol. 2008 Jan 24;123(3):234-9. Epub 2007 Apr 16. Review.

Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis. 2007 May;18(3):193-9.

Rubboli A, Di Pasquale G. The combination of anticoagulant and anti-platelet therapy in patients with atrial fibrillation: a comment on the recent ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J. 2006 Dec;27(23):2908-9; author reply 2909-10. Epub 2006 Oct 30.

Rubboli A, Milandri M, Castelvetri C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology. 2005;104(2):101-6. Epub 2005 Jul 12.

Rubboli A, Colletta M, Di Pasquale G. Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation. Am Heart J. 2005 Feb;149(2):E1.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rubboli A, Saia F, Sciahbasi A, Bacchi-Reggiani ML, Steffanon L, Briguori C, Calabrò P, Palmieri C, Rizzi A, Imperadore F, Sangiorgi GM, Valgimigli M, Carosio G, Steffenino G, Galvani M, Di Pasquale G, La Vecchia L, Maggioni AP, Bolognese L; WARfarin and Coronary STENTing (WAR-STENT) Study Group. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. J Invasive Cardiol. 2014 Nov;26(11):563-9.

Rubboli A, Sciahbasi A, Briguori C, Saia F, Palmieri C, Moroni LA, Calabrò P, Leone AM, Franco N, Valgimigli M, Varani E, Santi M, Pasqualini P, Capecchi A, Piccalò G, Margheri M, di Pasquale G, Galvani M, Bolognese L, Gonzini L, Maggioni AP; WARfarin and coronary STENTing registry. In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. J Invasive Cardiol. 2013 Apr;25(4):170-6.

Rubboli A, Bolognese L, Di Pasquale G, Galvani M, La Vecchia L, Maggioni AP. A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):200-3. doi: 10.2459/JCM.0b013e3283212f07.


Responsible Party:	Aldo P. Maggioni, Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)
ClinicalTrials.gov Identifier:	NCT00722319 History of Changes
Other Study ID Numbers:	WS-1
Study First Received:	July 23, 2008
Last Updated:	August 11, 2011

Keywords provided by War-Stent Investigators:


oral anticoagulation warfarin percutaneous coronary intervention stent antiplatelet agents

Additional relevant MeSH terms:


Atrial Fibrillation Acute Coronary Syndrome Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases	Pathologic Processes Myocardial Ischemia Vascular Diseases Warfarin Anticoagulants

ClinicalTrials.gov processed this record on September 21, 2017

To Top